Veozah Liver Damage

Veozah Liver Damage:

Used by menopausal women

Weitz & Luxenberg is investigating cases of severe liver damage in women who took Veozah to treat meno- pausal hot flashes. The U.S. Food and Drug Administration (FDA) warns that using Veozah (fezolinetant), “can cause rare but serious liver injury.” If your clients used Veozah to treat menopausal hot flashes and developed a severe liver injury, reach out to us today. We can help you consider your client’s legal options. They may be entitled to seek financial compensation.

Z

FDA Says Taking Veozah Can Damage Your Liver

The lawsuits we are planning to file are based on this warning from the FDA. The agency issued a Drug Safety Communication regarding Veozah on September 12, 2024. This medication is approved to treat hot flashes due to menopause. However, serious damage to one’s liver is possible. The FDA added a warning enhancing grave concern of the risk of liver injury to the medication’s prescribing information. An earlier warning about performing baseline bloodwork already existed – but the warning was expanded to include instructions on when the medication can be started and when it should be stopped, as well as the need to monitor liver enzymes in a much shorter time period after initiating treatment. The new warning now requires monthly testing for the next two months after starting Veozah — in addition to the already existing testing protocol at months 3, 6, and 9.

This information was updated by the FDA after receiving a report about a patient with elevated liver blood test values, along with symptoms of liver damage. She had been taking the medication for roughly only 40 days, which is 50 days before the prior labelling recommended liver enzyme testing.

The agency notes that Veozah is a causal factor in women developing liver damage. It has advised you to stop taking Veozah immediately if you start experiencing any symptoms of liver damage and to reach out to your health professional.

Z

Danger from Using Veozah to Treat Hot Flashes

Veozah is a prescription medication approved by the FDA in May 2023. This nonhormonal medication is intended to reduce both the frequency and the “severity of moderate to severe hot flashes caused by menopause.” This medication falls under the category of neurokinin 3 (NK3) receptor antagonists. The drug is intended to restore the balance between the hormone estrogen and a “brain chemical called neurokinin B (NKB).” Veozah is meant to block activities of the NK3 receptor. NK3 helps the brain control your body temperature. “The fact that Veozah is nonhormonal may make it sound more enticing than other options out there,” says Ellen Relkin, W&L partner and practice group chair of our Drug and Medical Device Litigation unit. “Hot flashes can be disruptive, unpredictable, overwhelming, and inconvenient at best. However, if your clients are to encounter the foreseeable liver injury, that can be life threatening.”

Possible Symptoms of Liver Damage Due to Veozah

If you are taking Veozah and experience any of these symptoms, the FDA says your clients should
stop taking the medication immediately:

Z

Nausea.

Z

Vomiting

Z

Light-colored stools

Z

Unusual itching

Z

Dark urine

Z

Feeling more tired than usual

Z

Yellowing of the eyes or skin (jaundice)

Z

Swelling in the stomach area

Z

Pain in the right upper

Z

Abdomen

Veozah Liver Damage